- Home
- TLSI vs NRO Comparison
TLSI vs NRO Comparison
Compare TLSI & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- NRO
- Stock Information
- Founded
- TLSI 2010
- NRO 2003
- Country
- TLSI United States
- NRO United States
- Employees
- TLSI N/A
- NRO N/A
- Industry
- TLSI Medical Specialities
- NRO Finance/Investors Services
- Sector
- TLSI Health Care
- NRO Finance
- Exchange
- TLSI Nasdaq
- NRO Nasdaq
- Market Cap
- TLSI 204.0M
- NRO 156.7M
- IPO Year
- TLSI N/A
- NRO N/A
- Fundamental
- Price
- TLSI $4.74
- NRO $3.23
- Analyst Decision
- TLSI Strong Buy
- NRO
- Analyst Count
- TLSI 5
- NRO 0
- Target Price
- TLSI $10.90
- NRO N/A
- AVG Volume (30 Days)
- TLSI 153.4K
- NRO 239.4K
- Earning Date
- TLSI 08-13-2025
- NRO 01-01-0001
- Dividend Yield
- TLSI N/A
- NRO 11.41%
- EPS Growth
- TLSI N/A
- NRO N/A
- EPS
- TLSI N/A
- NRO N/A
- Revenue
- TLSI $32,141,000.00
- NRO N/A
- Revenue This Year
- TLSI $55.52
- NRO N/A
- Revenue Next Year
- TLSI $54.76
- NRO N/A
- P/E Ratio
- TLSI N/A
- NRO N/A
- Revenue Growth
- TLSI 46.20
- NRO N/A
- 52 Week Low
- TLSI $3.50
- NRO $2.51
- 52 Week High
- TLSI $6.04
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- TLSI 40.45
- NRO 52.98
- Support Level
- TLSI $4.85
- NRO $3.22
- Resistance Level
- TLSI $5.03
- NRO $3.27
- Average True Range (ATR)
- TLSI 0.28
- NRO 0.04
- MACD
- TLSI -0.04
- NRO 0.00
- Stochastic Oscillator
- TLSI 2.73
- NRO 75.00
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").